ECO Synthesis growth Codexis is expanding its ECO Synthesis manufacturing platform with data presentations planned at key industry events (TIDES USA) and has highlighted RNA therapeutics and siRNA market opportunities, signaling a sales opening for enzymatic manufacturing solutions in high-value RNA-based therapeutics.

Financial momentum Strong Q4 and FY2025 results with revenue growth and improved gross margins, plus a strategy to sustain profitability through cost controls, suggest capacity for larger, repeatable manufacturing agreements and potential upsell of scalable enzymatic processes.

Strategic partnerships Existing collaboration with Merck on technology transfer signals openness to long-term partnerships and higher-volume manufacturing deals, presenting a pathway for future licensing, co-development, or expanded capability rollouts.

RNA focused demand Positioning around RNA therapeutics and siRNA markets indicates rising demand for scalable, high-margin enzymatic manufacturing, creating opportunities for sales to biotech and pharma clients seeking alternative to chemical synthesis.

Global exposure Presence at industry conferences like TIDES USA and public updates on regulatory engagement imply active market visibility and pipeline development, offering opportunities to engage early with potential customers exploring ECO Synthesis for their complex therapeutic programs.